Chinese firms Hepagene Therapeutics and EAVision Technologies have raised fresh funding.
Temasek backs EAVision in Series C
Suzhou-headquartered Chinese agricultural drone startup EAVision Technologies has secured $30 million in its Series C round co-led by Singapore’s state investor Temasek.
State-backed CITIC Agriculture along with Chinese agrifood tech VC Bits x Bites also joined as the co-lead investors, the investee said in a statement on Tuesday.
Strategic investors German BASF, US-based Continental Grain Company and Chinese fresh fruit retailer Pagoda also invested in the round, which was joined by Oriza Holdings, Zhidao Capital, Songshan Capital and Yongxin Oriental.
EAVision will use the proceeds to enhance R&D and to accelerate market expansion in China and beyond.
EAVision develops agricultural robots and drones driven by unmanned aerial vehicle technology.
“EAVision has developed an innovative and highly sophisticated technology that has the potential to significantly improve efficiency in the application of crop protection products,” said BASF Venture Capital GmbH managing director Markus Solibieda in the statement.
Hepagene nets $40m in Series B1
Clinical stage drug discovery and development firm Hepagene Therapeutics Inc on Tuesday said it has garnered a total of $40 million in its Series B1 round led by ByteDance-backer Loyal Valley Capital.
Oceanpine Capital and existing investor Apricot Capital joined the round.
The company will use the proceeds to support the clinical research of pipeline candidates, it said.
Since its inception in 2016, Hepagene has been engaged in the therapy areas targeting liver diseases such as non-alcoholic steatohepatitis, chronic Hepatitis B infection and cancer.